Deutsch
 
Benutzerhandbuch Datenschutzhinweis Impressum Kontakt
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT

Freigegeben

Zeitschriftenartikel

Cerebral ischemic preconditioning - An experimental phenomenon or a clinical important entity of stroke prevention?

MPG-Autoren
/persons/resource/persons147281

Schaller,  Bernhard
Wolf-Dieter Heiss, Emeriti, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

/persons/resource/persons147176

Graf,  Rudolf
Multimodal Imaging of Brain Metabolism, Research Groups, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Externe Ressourcen
Es sind keine Externen Ressourcen verfügbar
Volltexte (frei zugänglich)
Es sind keine frei zugänglichen Volltexte verfügbar
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Schaller, B., & Graf, R. (2002). Cerebral ischemic preconditioning - An experimental phenomenon or a clinical important entity of stroke prevention? Journal of Neurology, 249(11), 1503-1511.


Zitierlink: http://hdl.handle.net/11858/00-001M-0000-0026-D2E4-2
Zusammenfassung
Copyright 2002 Springer Verlag
Neurons can be preconditioned by various procedures to resist ischemic events. The preconditioning mechanism induced is characterized by a brief episode of ischemia that renders the brain more resistant against subsequent longer ischemic events. This ischemic tolerance has been shown in numerous experimental models of cerebral ischemia. The basic molecular mechanisms of ischemic tolerance are largely unknown. During the induction phase N-methyl-O-aspartate and adenosine receptors and, possibly, oxygen free radicals and conservation of energy metabolism are required. Protein kinases, transcription factors, and immediate early genes appear to transduce the signal into a tolerant response. Although the mechanism of ischemic tolerance remains uncertain, its discovery provides the focus for further understanding of the mechanism of endogenous neuroprotection and the potential of novel therapeutic strategies for neuroprotection. Such neuroprotective strategies may extend beyond ischemic tolerance to include other brain injury states as well.